Argus raised the firm’s price target on Bio-Techne (TECH) to $68 from $65 and keeps a Buy rating on the shares. While the company faces near-term headwinds, its end markets are displaying signs of improvement, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: